APA (7th ed.) Citation

A, P., M, M., F, M., M, A., AV, M., C, D. S., . . . G, D. Z. (2026). Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of Patients. Acta dermato-venereologica, 106, . https://doi.org/10.2340/actadv.v106.adv-2026-0336

Chicago Style (17th ed.) Citation

A, Pira, et al. "Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of Patients." Acta Dermato-venereologica 106 (2026). https://doi.org/10.2340/actadv.v106.adv-2026-0336.

MLA (9th ed.) Citation

A, Pira, et al. "Distinctive Reactivity to the C-terminal Epitope of BP180 Characterizes Immune Checkpoint Inhibitor-associated Bullous Pemphigoid, and an ELISA Based on the BP180 Ectodomain Enables Prompt Diagnosis in a Subset of Patients." Acta Dermato-venereologica, vol. 106, 2026, https://doi.org/10.2340/actadv.v106.adv-2026-0336.